PPWP
AMLX icon

Premier Path Wealth Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Premier Path Wealth Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Sell
18,265
-2,000
-10% -$30.9K 0.04% 346
2026
Q1 		$282K Hold
20,265
– – 0.04% 354
2025
Q4 		$245K Hold
20,265
– – 0.03% 361
2025
Q3 		$275K Hold
20,265
– – 0.04% 345
2025
Q2 		$130K Hold
20,265
– – 0.02% 384
2025
Q1 		$71.7K Buy
+20,265
New +$72.1K 0.01% 372
2024
Q4 		– Sell
-20,265
Closed -$65.7K – 370
2024
Q3 		$65.7K Buy
+20,265
New +$45.6K 0.01% 364
2024
Q2 		– Sell
-20,265
Closed -$57.6K – 369
2024
Q1 		$57.6K Hold
20,265
– – 0.01% 343
2023
Q4 		$298K Buy
+20,265
New +$311K 0.07% 261

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Premier Path Wealth Partners's AMLX Position: Q2 2026 in Review

Premier Path Wealth Partners reduced its Amylyx Pharmaceuticals (AMLX) stake by 9.9% in Q2 2026, selling an estimated $30.9K and leaving 18,265 shares worth $328K. The position accounts for 0.04% of the portfolio, ranked #346.

Premier Path Wealth Partners first reported a position in AMLX in Q4 2023 and has held it in 9 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Premier Path Wealth Partners held 18,265 shares of Amylyx Pharmaceuticals worth $328K as of Q2 2026.
  • Premier Path Wealth Partners sold 2,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $30.9K.
  • Amylyx Pharmaceuticals made up 0.04% of Premier Path Wealth Partners's portfolio in Q2 2026, its #346 holding.
  • Premier Path Wealth Partners first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.